Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Fresenius Medical Care announces acquisition of Hema Metrics assets related to Crit-Line system

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced the acquisition of all assets of Hema Metrics LLC related to its Crit-Line system.

8 Mar 2011

URMC research confirms possible use of mifepristone for painful fibroids

Research continues to show that the controversial abortion drug mifepristone might have another use, as a therapeutic option besides hysterectomy for women who suffer from severe symptoms associated with uterine fibroids.

8 Mar 2011

UTHealth study: Children with H. pylori infection have lower levels of iron

Children without previous iron deficiencies or anemia who remained infected with Helicobacter pylori had significantly lower levels of iron compared to children who had the infection eradicated, according to researchers at The University of Texas Health Science Center at Houston.

8 Mar 2011

FDA approves change to prescribing information for Gilead Sciences' Letairis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.

5 Mar 2011

Dentists need to take a closer look at potential hazards of exposing patients to zinc

Dentists need to take a closer look at potential hazards of exposing patients to zinc, a common ingredient of many dental products, according to a report by Amar Patel, DDS, resident and colleagues at the University of Maryland Dental School in the March/April 2011 issue of the journal General Dentistry.

4 Mar 2011

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos Therapeutics, Inc. today announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) under its Special Protocol Assessment (SPA) process for the design of the Company's Phase 3 clinical trial of FOLOTYN® (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL).

4 Mar 2011

VICC introduces nation's first personalized cancer decision support tool

Vanderbilt-Ingram Cancer Center has launched the nation's first personalized cancer decision support tool, "My Cancer Genome," to help physicians and researchers track the latest developments in personalized cancer medicine and connect with clinical research trials for their patients.

3 Mar 2011

Rockwell Medical fourth quarter net loss increases to $1.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today fourth quarter and full-year 2010 results.

3 Mar 2011

International consortium of researchers genetically characterise Spanish Fanconi anaemia patients

A consortium of thirty-two researchers worldwide, led by Dr Jordi Surrallés, professor of the Department of Genetics and Microbiology at Universitat Autònoma de Barcelona (UAB) and member of the Centre for Biomedical Network Research on Rare Diseases (CIBERER), genetically and clinically characterised almost all Spanish patients suffering from Franconi anaemia, a rare disease affecting one in every 500,000 persons and which is characterised by severe anaemia in children, congenital malformations and a high predisposition to cancer.

3 Mar 2011

Mathematical model predicts lifespan of stem cells

When patients receive a bone marrow transplant, they are getting a new population of hematopoietic stem cells. Fresh stem cells are needed when a patient is low on red blood cells, as in anemia, or white blood cells, which can be caused by cancer or even cancer treatments such as irradiation or chemotherapy. The problem is that a bone marrow transplant might not succeed because the transplanted stem cells don't live long enough or because they proliferate too well, leading to leukemia.

2 Mar 2011

Scientists discover lead contamination in ceramic cookware sold in Philadelphia's Chinatown

Recently, a research team from the Department of Emergency Medicine at Jefferson Medical College of Thomas Jefferson University discovered an alarming amount of lead contamination in ceramic cooking and eating utensils sold in Philadelphia's Chinatown.

1 Mar 2011

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review classification to its Supplemental New Drug Application (sNDA) regarding ISTODAX (romidepsin) for injection for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.

28 Feb 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion Pharmaceuticals, Inc. joins the European Organization for Rare Diseases, the National Organization for Rare Disorders and families, governments, companies and medical communities around the world in observing the fourth annual Rare Disease Day today.

28 Feb 2011

Scripps Health offers genetic testing to patients with Hepatitis C

Scripps Health is one of the first health systems in the United States to offer genetic testing as part of its care for hepatitis C patients planning to undergo drug treatment.

28 Feb 2011

AMAG fourth quarter total revenues increase to $17.2 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2010.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Study: Newborn screening for hemoglobin H disease can reduce mortality rate

A new and groundbreaking study conducted by Children's Hospital & Research Center Oakland hematologists is the first of its type to examine the natural history of heritable blood disorder hemoglobin H (HbH) which is on the rise in the United States.

24 Feb 2011

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

24 Feb 2011

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii.

22 Feb 2011

Anemia News and Research

Further Reading

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Fresenius Medical Care announces acquisition of Hema Metrics assets related to Crit-Line system

URMC research confirms possible use of mifepristone for painful fibroids

UTHealth study: Children with H. pylori infection have lower levels of iron

FDA approves change to prescribing information for Gilead Sciences' Letairis

Dentists need to take a closer look at potential hazards of exposing patients to zinc

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

VICC introduces nation's first personalized cancer decision support tool

Rockwell Medical fourth quarter net loss increases to $1.7 million

International consortium of researchers genetically characterise Spanish Fanconi anaemia patients

Mathematical model predicts lifespan of stem cells

Scientists discover lead contamination in ceramic cookware sold in Philadelphia's Chinatown

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Scripps Health offers genetic testing to patients with Hepatitis C

AMAG fourth quarter total revenues increase to $17.2 million

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Study: Newborn screening for hemoglobin H disease can reduce mortality rate

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News